CIMAC

CSL Leads Maritime Industry in Biofuel Adoption, Achieving Milestones in Decarbonization Efforts

Retrieved on: 
Friday, December 8, 2023
NOx, Sulfur oxide, International Council, Government, GHG, International Maritime Organization, Original equipment manufacturer, Ship, CSL, CIMAC, Canada Steamship Lines, Carbon, Organization, Steel, CO2, B80

MONTREAL, Dec. 08, 2023 (GLOBE NEWSWIRE) -- The CSL Group (“CSL”), a global leader in responsible marine transportation services, proudly announces a significant milestone in its Great Lakes biofuel program – one of the longest-running initiatives of its kind in the maritime industry.

Key Points: 
  • MONTREAL, Dec. 08, 2023 (GLOBE NEWSWIRE) -- The CSL Group (“CSL”), a global leader in responsible marine transportation services, proudly announces a significant milestone in its Great Lakes biofuel program – one of the longest-running initiatives of its kind in the maritime industry.
  • With a cumulative 75,000 running hours on B100 biofuel over the past four years, CSL ships have made significant strides in supporting decarbonization efforts by replacing 55,000 metric tonnes of fossil fuel with biodiesel and avoiding 156,000 metric tonnes of CO2.
  • “Biofuel offers a practical and low-risk solution toward a decarbonized marine industry, but we need government support to ensure it remains affordable.
  • CSL is proud to lead the way in showcasing the effectiveness of biofuel, and we call on governments and industry stakeholders to accelerate the adoption of sustainable practices in maritime transportation.”
    Since 2019, CSL’s biofuel program has played a pivotal role in shaping industry standards.

Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, September 26, 2023
Survivor, ICIS, University, ICI, Cohort, Overalls, Survival, Clinical trial, OS, Quality of life, Lung cancer, National Cancer Institute, University of Pennsylvania, NK, Research, Toxicity, Doctor of Philosophy, Associate, PACT, ASCO, CIMAC, Patient, Perelman School of Medicine at the University of Pennsylvania, Immune system, Aggarwal, Toxic epidermal necrolysis, MPH, Therapy, CADL, Tumor microenvironment, Safety, Disease, Pharmaceutical industry, Vaccine, Candel, NSCLC, Fellow of the Academy of Medical Sciences, MD

These patients historically have had an expected median overall survival of 10-13 months (Reckamp K et al.

Key Points: 
  • These patients historically have had an expected median overall survival of 10-13 months (Reckamp K et al.
  • Candel expects to share topline overall survival data for Cohort 2 in the second quarter of 2024, assuming mature data at that time.
  • “We are very encouraged by the initial survival data, particularly for Cohort 2 which enrolled patients whose disease progressed despite receiving anti-PD(L)1 treatment.
  • I look forward to the maturation of these overall survival data and expected readout in Q2 2024.”

Candel Therapeutics and Partnership for Accelerating Cancer Therapies (PACT) to Collaborate on Lung Cancer Trial for CAN-2409

Retrieved on: 
Friday, December 10, 2021
Private Securities Litigation Reform Act, Patient, FNIH, MD, SEC, Cancer, Nasdaq, Disease, CIMAC, CADL, ICI, Research, PACT, CIDC, GLOBE, Doctor of Philosophy, HSV, Trial of the century, Clinical trial, Large-cell lung carcinoma, PD-L1, Company, National, Prostate cancer, Content discovery platform, Partnership, Pancreatic cancer, Therapy, Combination therapy, Tumor microenvironment, Foundation, Immunotherapy, Neoplasm, Herpes simplex virus, Immunogenic cell death, Vaccine, Pharmaceutical industry, Online shopping

Analysis of longitudinal biologic samples from a Candel phase 2 clinical trial will be performed by the CIMAC-CIDC research centers and sponsored by PACT.

Key Points: 
  • Analysis of longitudinal biologic samples from a Candel phase 2 clinical trial will be performed by the CIMAC-CIDC research centers and sponsored by PACT.
  • The assays proposed include in depth immunophenotyping of serial lung biopsies and peripheral blood samples obtained during the clinical trial.
  • Currently, Candel is evaluating the effects of treatment with CAN-2409 in non-small cell lung cancer, high-grade glioma, pancreatic cancer, and localized, non-metastatic prostate cancer in ongoing clinical trials.
  • Candel has established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.